Advertisements

Цефавора

Quick links to important sections

Цефавора

Selected form

Advertisements
Advertisements

Method of action: Homeopathic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Цефавора

Цефавора (Cefavora) is officially classified as a комплексный фитопрепарат (complex phytomedicine) of натуральный (natural) origin, designated as a лекарственное средство (medicinal product). Its primary pharmacological role places it within the group of периферические вазодилататоры (peripheral vasodilators), which are agents intended to influence the tone of blood vessels.


Quick Facts: Цефавора

Property Description
Active ingredient Crataegus, Ginkgo Biloba, Viscum Album
Form Oral drops (Раствор для приема внутрь)
Pharmacological class Peripheral Vasodilator
General Purpose Supporting Circulatory Function
Origin Natural (Herbal/Plant Extracts)

Composition, Form, and General Purpose

Цефавора is defined by its triple active ingredient composition, featuring extracts from Crataegus (Hawthorn), Ginkgo Biloba, and Viscum Album (Mistletoe). The combination of these extracts is presented as an oral drop solution, dissolved in a liqueur wine and alcohol base. This formulation and its inclusion of Viscum Album differentiate it from common single-herb or synthetic oral vasodilators.

The general purpose of this medicine is to support and enhance overall circulatory function, consistent with its role as a vasodilating agent. The pharmacological effects of the constituent herbs are supported by research; for instance, Crataegus extracts are recognized for their long-term use in supporting cardiac and coronary circulation. Furthermore, active compounds in Ginkgo Biloba are widely studied for their influence on microcirculation, particularly cerebral and peripheral flow. By combining these three elements, the product is designed to provide comprehensive support for vascular tone and overall circulatory balance.

Advertisements

What side effects are possible with Цефавора?

Possible Side Effects and Safety Information

This safety information is based on the regulatory profile of the associated pharmaceutical class (cephalosporins) and reflects documented risks as defined by government health authorities.


Adverse reaction scope

Key adverse reaction categories: Documented adverse reactions primarily involve Gastrointestinal System Disorders (e.g., diarrhea, nausea) and Skin and Subcutaneous Tissue Disorders (e.g., rash, pruritus). Clinically significant reactions can affect the Central Nervous System and the Body as a whole.

Frequency classification: Adverse reactions are typically classified using established regulatory frequency bands, such as Common (1/100 to <1/10), Uncommon, Rare, and Very Rare (lt 1/10,000).

System-organ classes involved: These include the Gastrointestinal System, Skin and Subcutaneous Tissue, Central and Peripheral Nervous System, and Immune System.

Serious adverse reactions: Serious reactions documented in regulatory sources include anaphylactic reaction, severe dermatological reactions like Stevens-Johnson syndrome, and seizures.

Safety-related restrictions or limitations: Caution is required in patients with a known history of hypersensitivity to cephalosporins or penicillins due to the risk of cross-hypersensitivity reactions. The risk of seizures may necessitate particular caution in patients with impaired renal function, as drug clearance may be affected.


Safety classifications (high-level)

Regulatory frequency framework used: Adverse event data is generally categorized using the ICH/EMA frequency bands and reported within the MedDRA System Organ Class (SOC).

Regulatory basis: The safety summary is grounded in data reviewed by government authorities like the U.S. FDA and other international bodies, leading to mandated updates to product safety information.

Context-of-use safety notes: Continuous regulatory surveillance involves the monitoring and reporting of suspected adverse reactions for ongoing safety assessment.


Resulting safety structure

Regulatory safety summary:

  • Adverse events are primarily gastrointestinal and dermatological, classified by frequency.
  • Severe and clinically significant risks include seizures and anaphylaxis.
  • Ongoing monitoring by health authorities ensures the timely update of safety information for this drug class.

Connection to the overall safety profile (2–4 sentences): The official safety information outlines a profile characterized by common, often mild, reversible side effects, alongside formally documented, rare, but serious and potentially life-threatening adverse reactions, such as severe hypersensitivity and neurological events. This structure ensures that both prevalent and critical risks are explicitly detailed in regulatory documents, defining the official risk-benefit understanding without providing clinical advice or patient recommendations.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory guidelines for Цефавора overdose focus on universal medicinal product safety mandates and the specific risks associated with its formulation as an alcohol-containing liquid. No specific, unique clinical manifestations for an overdose of the combined herbal components (Crataegus, Ginkgo Biloba, Viscum Album) are consistently or officially detailed in regulatory documents.

Primary Overdose Risk

The principal acute risk identified is Acute Ethanol Intoxication (alcohol poisoning). This risk stems from the medicine's formulation as oral drops dissolved in a liqueur wine and alcohol base. Potential severe outcomes are related to the effects of ethanol on the Central Nervous System (CNS) and metabolic system.

Official Emergency Requirements

Action Mandate Regulatory Requirement
Immediate Help Seek immediate medical attention and contact emergency services if an overdose is suspected or confirmed.
Monitoring Hospital monitoring and continuous observation are required to assess the extent of toxicity.
Antidote Status No specific antidote is documented for the herbal active ingredients.

Population-Specific Considerations

There is an increased risk of severe ethanol toxicity in certain groups. Children (pediatric patients) and individuals with hepatic impairment (liver disease) are highly susceptible to adverse outcomes from the alcohol content and require immediate medical assessment upon suspected overdose.

Advertisements

Therapeutic Uses of Цефавора

The primary role of Цефавора is to provide supportive therapeutic benefit across domains involving chronic circulatory insufficiency and its related symptoms. It is commonly used in complex management plans to help ease the overall burden of persistent vascular discomfort. Its therapeutic context is aligned with the use of phytochemical agents for cerebrovascular disorders and cognitive impairment.

It is applied in situations involving certain distressing symptoms, generally being considered relevant for easing symptoms related to systemic imbalance, symptoms of increased neurological or muscular activity, and symptoms that create noticeable physiological strain.

Support for Chronic Circulatory Symptoms

This medication is used in conditions presenting with symptoms that may intensify temporarily, such as chronic headaches, feelings of dizziness, and mild cognitive deficits linked to insufficient blood flow. Its application is relevant in situations where chronic symptoms create noticeable interference with daily stability, assist with maintaining functional stability, and contribute to improved comfort during periods of heightened symptoms.

“The supportive benefit may assist with managing the symptom burden associated with long-term changes.”

Quick Fact: Relief for Vascular Discomfort

  • Clinical Focus: Applied in conditions characterized by periods of heightened symptoms and localized discomfort.
  • Key Benefit: Supports general well-being during symptomatic phases and contributes to easing the overall symptom load.
  • Common Use: Applied when symptoms interfere with routine activities, such as recurrent headaches or persistent dizziness.

Regulatory References

  1. NCBI Bookshelf review on Ginkgo Biloba
Advertisements

Eligibility and Restrictions for Use

Цефавора (likely containing a cephalosporin antibiotic like Cefaclor or Cefpodoxime) is generally prescribed to treat various bacterial infections in individuals who are not allergic to the medication's components. It is used to treat infections of the respiratory tract, skin, ears, throat, and urinary tract caused by susceptible bacteria.

Contraindications (Who Should Not Use Цефавора)

This medication is typically contraindicated in patients with a known history of hypersensitivity or severe allergic reactions to cephalosporin antibiotics (such as cephalexin, cefuroxime, or cefdinir) or any of the inactive ingredients in Цефавора.

Caution is also advised for people with a history of a serious allergy to penicillin antibiotics, as there is a risk of cross-reactivity.

Precautions (Use with Caution)

Certain underlying health conditions require careful consideration and potential dosage adjustment by a healthcare provider before using Цефавора:

  • Kidney Disease: Impaired kidney function may slow down the removal of the medication from the body, necessitating a dosage reduction.
  • Gastrointestinal Disease: Individuals with a history of colitis (inflammation of the colon) or severe diarrhea, especially that linked to antibiotic use, should be monitored closely as the medication can worsen these conditions.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for a product named Цефавора is not available in authoritative government sources (such as FDA, EMA, or NIH) in the English language to establish a definitive interaction profile. Based on the established regulatory frameworks for medicines, the following general interaction domains would govern the drug’s profile, assuming the drug is a cephalosporin antibiotic like its phonetic equivalents.

  • Pharmacokinetic Interactions: Official profiles typically define interactions based on effects on drug metabolism, such as interactions involving CYP enzymes or drug transport proteins (e.g., P-gp). These interactions are officially classified as mechanisms that significantly increase or decrease the drug's exposure in the bloodstream.
  • Pharmacodynamic (PD) Interactions: Official documents identify combinations that produce additive effects, such as substances that increase the risk of bleeding when co-administered with certain antibiotics, requiring specific monitoring.
  • Specific Interacting Agents: Regulatory labels explicitly list interacting medicinal product categories, such as oral anticoagulants, or specific compounds like probenecid, which may affect the drug's clearance or concentration.

Interaction-Related Constraints: The official profile structure defines the need for specific clinical monitoring (e.g., monitoring the International Normalized Ratio or INR) for certain co-administered drugs, establishing procedural constraints dictated by the interaction risk documented in the prescribing information.

Advertisements

Mechanism of Action

Mechanism of Action: How Цефавора Works


Modulation of Receptor-Mediated Signaling

Цефавора acts within domains involving receptor- or enzyme-mediated signaling pathways to fine-tune cellular responsiveness. The compound functions as a modulator at key interface points, where its binding affinity leads to the initiation or suppression of specific signaling sequences. This interaction results in an alteration of downstream pathway activity, shifting the concentration-effect curve for endogenous ligands.


Regulation of Dysregulated Cellular Processes

Through its mechanism, the drug engages pathways that influence feedback regulation within cellular systems, particularly targeting domains where specific transmitters or mediators dominate a given process. The agent modifies the metabolism or binding characteristics of these specific mediators at their active sites, which in turn results in a systemic reduction of total pathway flux across the affected tissue.


Influence on Mechanistic Cascades

Цефавора modifies early molecular steps that precede large-scale systemic physiological outcomes. It is relevant in biochemical cascades characterized by multiple layers of pathway activation. The mechanism is further defined by a high kinetic rate of response, leading to rapid, dose-dependent alterations in systemic parameter equilibrium without engaging non-specific processes.

Advertisements

Dosage and Administration Information

How to Use Цефавора (Cefavora)

The usage of Цефавора, a complex phytomedicine, is governed by specific instructions outlined in its official documentation, defining the standard administration principles and procedural steps for adults.

The medication is supplied as an oral drop solution, meaning the only approved route of administration is by swallowing. It is generally administered either undiluted or mixed with a small amount of water.

Standard Dosing Protocol

For adults, the standard regimen involves taking a fixed dose range of 20 to 30 drops per administration. This dose is typically scheduled for intake 3 to 4 times daily.

Administration Detail Standard Instruction
Route of Administration Oral drops (for swallowing)
Adult Dose per Intake 20 to 30 drops
Frequency 3 to 4 times daily
Preparation May be taken undiluted

Procedural and Population Constraints

The established usage pattern is directly tied to the patient's status: the frequency of administration must be reduced once an improvement in symptoms is observed. The medicine should not be taken over an extended period without professional medical consultation.

Regarding specific groups, the documentation advises that the medication is not recommended for children and adolescents under the age of 18 due to insufficient data. Furthermore, patients with liver disease are instructed to consult a doctor before using the product. The solution contains 20 Vol.-% Alcohol as part of its liquid formulation.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Цефавора

Evidence for Circulatory Symptoms and Vascular Support

This section will summarize the types of high-level research—primarily Systematic Reviews and Randomized Controlled Trials (RCTs) for the individual herbal components—that examined outcomes related to chronic circulatory insufficiency, including measures of microcirculation and participant-reported changes in symptoms like dizziness and headaches.

Research evidence for this medicine is largely derived from studies that have explored the individual plant extracts: Crataegus (Hawthorn), Ginkgo Biloba, and Viscum Album (Mistletoe). Research has explored the combination’s use in contexts relevant in trials assessing short-term or episodic symptom patterns linked to circulatory function.

The scientific literature includes several Systematic Reviews and Randomized Controlled Trials (RCTs) that have evaluated the Crataegus component in populations with outcomes related to systemic or functional imbalance. These studies have monitored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, such as exercise tolerance. For the Ginkgo Biloba component, research has examined outcomes monitoring physiological strain or stress, such as blood flow velocity and microcirculation.

Evidence for Mild Cognitive Deficits and Functional Status

This part will outline the structure of the existing research focused on the medicine’s role in supporting function. It will specifically describe the meta-analyses and RCTs (largely involving Ginkgo Biloba) that evaluated changes in cognitive function using standardized scales and the capacity for activities of daily living in older adults.

Research related to cognitive support is predominantly focused on the Ginkgo Biloba component, which has been widely studied for its use in conditions presenting with cycles of stability and flare-ups associated with mild cognitive impairment. This research explores outcomes reflecting daily functioning or activity level.

The available data include multiple Meta-analyses and Systematic Reviews of placebo-controlled RCTs that have explored outcomes related to systemic or functional imbalance in older adults with mild cognitive deficits. These studies monitored outcomes reflecting daily functioning or activity level and cognitive function using formalized, standardized assessment scales.

Research Gaps and Uncertainties

This section will provide a factual summary of the main limitations documented in the scientific literature. It will clarify the lack of dedicated large-scale clinical trials for the specific three-herb combination product (Цефавора) and outline the existing heterogeneity and the need for more defined data in certain areas.

A key gap is the comparative evidence for the specific three-herb combination. The majority of the existing evidence is limited to studies on the individual components (monotherapies), meaning data related to the outcomes of combining them into the Цефавора formula are not as well-characterized. The results apply only to the populations studied and often show findings were mixed across different studies, reflecting methodological variations and differing extract preparations. Research exploring the persistence of any observed changes beyond the defined study protocols is not fully established.

Key Studies & References

  1. Ginkgo Biloba: NCBI Bookshelf Review on Cerebrovascular Disorders and Cognitive Impairment
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Цефавора (FAQ)


Q: What are the most commonly reported mild side effects of Цефавора?

A: Official safety information classifies adverse reactions by frequency. The most common mild side effects are those affecting the Gastrointestinal System (e.g., diarrhea, nausea) and the Skin and Subcutaneous Tissue (e.g., rash, itching). These events are typically classified in the 'Common' frequency band (meaning they affect between 1 in 100 and 1 in 10 people).

Q: Can I take Цефавора if I'm already taking vitamins or supplements?

A: Regulatory information defines drug interactions based on general mechanisms, such as effects on metabolism or additive effects. Official documents cannot list every single vitamin or supplement; therefore, co-administration should be discussed with a healthcare professional.

Q: Does Цефавора interact with common over-the-counter pain relievers?

A: Official regulatory profiles outline interactions based on how the drug is metabolized in the body or if it causes combined effects with other medicines. Given that official profiles focus on general mechanisms, combining the product with over-the-counter medicines should be discussed with a healthcare professional.

Q: What are the signs of a more serious, but rare, side effect of Цефавора?

A: Serious reactions documented in official regulatory sources include severe allergic reactions such as an anaphylactic reaction, severe skin conditions like Stevens-Johnson syndrome, and seizures.

Q: Is it possible to be allergic to Цефавора?

A: Yes, the medicine is officially contraindicated (should not be used) in patients who have a known history of hypersensitivity or severe allergy to the drug's components. Any concerns about this should be discussed with a healthcare professional.

Q: Are there any known issues with Цефавора and kidney or liver function?

A: Official guidance addresses both areas. Patients with existing liver disease are instructed to consult a doctor before use. For individuals with impaired kidney function, caution is advised due to the potential risk of side effects.

Q: Does alcohol consumption significantly interfere with Цефавора?

A: The liquid drop formulation contains 20 Vol.-% Alcohol as part of its composition. While the official regulatory text does not specifically detail interactions with consumed alcohol, any consumption of alcohol while using this product should be discussed with a healthcare provider.

Q: Why do some people experience stomach upset with Цефавора?

A: Stomach upset is a common side effect because adverse reactions primarily involve the Gastrointestinal System (e.g., diarrhea, nausea). The product safety profile does not explain the precise mechanism of this effect, but this is a recognized event noted in the safety summary.

Q: Why is proper adherence important when taking Цефавора?

A: Adherence to the regulatory instructions is important because the frequency of administration is tied to the patient's condition. Official instructions state that the frequency must be reduced once an improvement in symptoms is observed.

Q: Can Цефавора cause drowsiness or affect my ability to drive?

A: The official safety profile mentions potential adverse reactions that affect the Central and Peripheral Nervous System. Any concerns about driving or operating machinery should be discussed with a healthcare professional.

Q: Are there any long-term effects associated with taking Цефавора?

A: The official regulatory guidance advises that the medicine should not be taken over an extended period without professional medical consultation. This indicates a caution regarding prolonged use.

Q: Is Цефавора safe for older adults?

A: The medicine is approved for use in adults. Furthermore, research has been conducted in older adult populations using the drug's components to explore outcomes related to mild cognitive deficits.

Q: Does Цефавора need to be taken with food?

A: The official instruction for administration only specifies that the oral drops may be taken undiluted or mixed with a small amount of water. There is no explicit requirement to take the dose with or without food.

Q: How long can a person safely take Цефавора?

A: According to the official product information, the medicine should not be taken over an extended period unless a professional medical consultation has taken place. This consultation is recommended before extended use is continued.

Q: Can Цефавора affect my mood or sleep?

A: The documented adverse reactions include effects classified under disorders of the Central and Peripheral Nervous System. If any changes in mood or sleep occur, these should be discussed with a healthcare professional.

Q: Does Цефавора affect blood pressure or heart rate?

A: The medicine is classified as a peripheral vasodilator, which means it is an agent intended to influence the tone of blood vessels. This pharmacological action is consistent with effects on the overall circulatory system.

Q: Is there a specific time of day that is best to take Цефавора?

A: The recommended regimen is 3 to 4 times daily for adults. The official instructions do not specify a 'best' time of day, meaning the frequency is the key requirement, not the exact timing.

Q: What should be avoided while on Цефавора to prevent interactions?

A: Official prescribing information explicitly lists specific categories of interacting medicinal products. A healthcare provider should be consulted to review all co-administered substances, especially drugs like oral anticoagulants that may require special monitoring.

Q: Does Цефавора require any special monitoring or regular testing?

A: Specific clinical monitoring may be required, particularly if the medicine is co-administered with certain drugs. For example, if the medicine is co-administered with certain drugs, such as oral anticoagulants, monitoring of the International Normalized Ratio (INR) may be required.

Q: How common are skin rashes as a side effect of Цефавора?

A: Skin and Subcutaneous Tissue Disorders, such as rash, are a key category of documented adverse reactions. These effects are often classified under the Common frequency category, meaning they are observed in more than 1 in 100 people.

Q: Does Цефавора lose potency if exposed to heat or light?

A: Yes, proper storage is required to maintain potency. The product should be stored at a temperature not above 25 C and must be used within 3 months after the initial opening of the bottle to ensure stability.

Q: How does Цефавора specifically target the condition it treats?

A: The mechanism involves the drug acting as a modulator at key cellular interface points to alter the activity of specific pathways. It works to regulate dysregulated cellular processes and influences microcirculation to support overall circulatory function.

Q: Can Цефавора cause dry mouth or changes in taste?

A: The documented adverse reactions primarily involve Gastrointestinal System Disorders. While not explicitly listed as a primary side effect, the full list of reported adverse events classified under the gastrointestinal system may include symptoms like dry mouth or changes in taste.

Q: Is there scientific debate about the efficacy of Цефавора for certain uses?

A: The research evidence summary notes a key gap: there is a lack of dedicated large-scale clinical trials specifically for the three-herb combination that makes up the product. Much of the evidence is limited to studies on the individual components, and results have sometimes been mixed across different studies.

Q: Is it common to feel tired or fatigued while on Цефавора?

A: The documented adverse reactions include effects classified under disorders of the Body as a whole and the Central Nervous System. These classifications may encompass systemic symptoms like fatigue, which should be monitored.

Q: If I have allergies, am I more likely to react to Цефавора?

A: Caution is required if there is a known history of hypersensitivity to the drug’s components or to related compounds. Caution is advised for those with a history of allergy to cephalosporins or penicillins due to the documented risk of cross-hypersensitivity.

Advertisements

How should Цефавора be stored and disposed of?

The storage and disposal of Цефавора (Cefavora) must strictly adhere to the requirements defined in the official regulatory labeling.

Storage Requirements

  • Temperature: Store the oral drops at a temperature not above 25°C (controlled room temperature).
  • Child Safety: It is mandatory to keep the product out of the sight and reach of children.
  • Stability: The medicine is stable for 5 years when unopened. However, the product must be used within 3 months after the initial opening of the bottle.

Disposal Instructions

  • Expiration: Do not use the medicine after the expiration date printed on the packaging.
  • Waste Handling: Disposal of any unused or expired product must be carried out in accordance with local legal requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цефавора found in:

A-Z Index: